Earnings Preview For Caleres
Caleres (NYSE:CAL) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement. Analysts estimate that Caleres will report an earnings per share (EPS) of $0.85. Caleres bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next ...Full story available on Benzinga.com.....»»
Earnings Preview: Harrow Health
Harrow Health (NASDAQ:HROW) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement. Analysts estimate that Harrow Health will report an earnings per share (EPS) of $-0.04. Harrow Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the ...Full story available on Benzinga.com.....»»
Preview: Precigen"s Earnings
Precigen (NASDAQ:PGEN) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement. Analysts estimate that Precigen will report an earnings per share (EPS) of $-0.08. Precigen bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next ...Full story available on Benzinga.com.....»»
Earnings Preview: Citi Trends
Citi Trends (NASDAQ:CTRN) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement. Analysts estimate that Citi Trends will report an earnings per share (EPS) of $0.79. Citi Trends bulls will hope to hear the company announce they've not only beaten that estimate, but also ...Full story available on Benzinga.com.....»»
A Preview Of HUYA"s Earnings
HUYA (NYSE:HUYA) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement. Analysts estimate that HUYA will report an earnings per share (EPS) of $-0.12. HUYA bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next ...Full story available on Benzinga.com.....»»
Earnings Preview For Design Therapeutics
Design Therapeutics (NASDAQ:DSGN) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement. Analysts estimate that Design Therapeutics will report an earnings per share (EPS) of $-0.31. Design Therapeutics bulls will hope to hear the company announce they've not only beaten that ...Full story available on Benzinga.com.....»»
Orla Mining"s Earnings Outlook
Orla Mining (AMEX:ORLA) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement. Analysts estimate that Orla Mining will report an earnings per share (EPS) of $0.01. Orla Mining bulls will hope to hear the company announce they've not only beaten that estimate, but also to ...Full story available on Benzinga.com.....»»
Earnings Outlook For Relmada Therapeutics
Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement. Analysts estimate that Relmada Therapeutics will report an earnings per share (EPS) of $-0.83. Relmada Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the ...Full story available on Benzinga.com.....»»
Recap: Tango Therapeutics Q4 Earnings
Tango Therapeutics (NASDAQ:TNGX) reported its Q4 earnings results on Monday, March 18, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Tango Therapeutics missed estimated earnings by -14.000000000000002%, reporting an EPS of $-0.32 versus an estimate of $-0.28. Revenue ...Full story available on Benzinga.com.....»»
StoneCo Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
StoneCo Ltd. (NASDAQ: STNE) is expected to release its financial results for the fourth quarter, after the closing bell on March 18, 2024. Analysts expect the George Town, Cayman Islands-based company to report quarterly earnings at 30 cents per share, up from 15 cents per share in the year-ago period. Hibbett is projected to post revenue of $685.73 million for the latest quarter, compared to $549.66 million in the year-earlier quarter, according to data from Benzinga Pro. On Jan. 5, StoneCo said it received the Financeira License from the Brazilian Central Bank. The license is organized as a Sociedade de Crédito, Financiamento ...Full story available on Benzinga.com.....»»
Taysha Gene Therapies Earnings Preview
Taysha Gene Therapies (NASDAQ:TSHA) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement. Analysts estimate that Taysha Gene Therapies will report an earnings per share (EPS) of $-0.11. Taysha Gene Therapies bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, ...Full story available on Benzinga.com.....»»
Earnings Outlook For TeraWulf
TeraWulf (NASDAQ:WULF) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement. Analysts estimate that TeraWulf will report an earnings per share (EPS) of $-0.02. TeraWulf bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next ...Full story available on Benzinga.com.....»»
Leap Therapeutics: Q4 Earnings Insights
Leap Therapeutics (NASDAQ:LPTX) reported its Q4 earnings results on Monday, March 18, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Leap Therapeutics beat estimated earnings by 16.0%, reporting an EPS of $-0.46 ...Full story available on Benzinga.com.....»»
Dow Jumps Over 100 Points; US Housing Market Index Surges In March
U.S. stocks traded higher midway through trading, with the S&P 500 index gaining around 1% on Monday. The Dow traded up 0.37% to 38,859.32 while the NASDAQ rose 1.61% to 16,231.11. The S&P 500 also rose, gaining, 1.05% to 5,171.00. Check This Out: Top 4 Tech Stocks That May Collapse In March Leading and Lagging Sectors Communication services shares jumped by 3.6% on Monday. In trading on Monday, health care shares rose by just 0.2%. Top Headline The NAHB/Wells Fargo Housing Market Index rose to 51 in March, notching the highest reading in eight months, versus a reading of 48 in February and beating market estimates of 48. Equities Trading UP Canoo Inc. (NASDAQ: GOEV) shares shot up 53% to $2.98 after the US Department of Commerce has approved its Oklahoma City facility as a Foreign Trade Zone. Shares of Wearable Devices Ltd. (NASDAQ: WLDS) got a boost, surging 29% to $0.5750. Wearable Devices published a report by its XR ...Full story available on Benzinga.com.....»»
Recap: PEDEVCO Q4 Earnings
PEDEVCO (AMEX:PED) reported its Q4 earnings results on Monday, March 18, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Earnings PEDEVCO missed estimated earnings by -100.0%, reporting an EPS ...Full story available on Benzinga.com.....»»
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections.....»»
Nasdaq, S&P 500 Set For Strong Open As Nvidia AI Conference Buzz Eclipses Fed Jitters: Analyst Tells Why Investors Should Shrug Off March Slackness
Traders seem poised to overlook their inflation concerns as they anticipate the Federal Open Market Committee meeting scheduled for the week with optimism. Early Monday, stock futures showed mostly upward movement, with the tech sector potentially leading the way. Nvidia Corp.’s (NASDAQ:NVDA) GTC 2024, featuring CEO Jensen Huang‘s keynote, and the possibility of a partnership between Alphabet, Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) and Apple, Inc. (NASDAQ:AAPL), are expected to boost sentiment. However, bond yields are on the rise, reflecting lingering concerns about a hawkish message from the upcoming Federal Reserve meeting. Cues From Last Week’s Trading: Higher-than-expected consumer and producer price inflation data led to the major indices posting their second consecutive weekly losses. Small-cap and tech stocks were particularly affected, with all three major indices closing lower in the week ending March 15. The broader S&P 500 Index reached intra-day and closing highs on Tuesday before retracing following the release of the inflation data. The week also witnessed a spike in bond yields due to tempered expectations of rate cuts, accompanied by a sharp increase in the CBOE Volatility Index (VIX). Fund manager Louis Navellier commented on the week’s developments, stating, “The strong rally in equities since the end of October is finally showing some fatigue.” He noted that gains have slowed as expectations for Fed rate cuts are being pushed back, with June now the expected timeframe for the first rate cut, reflecting a 60% probability. Index Performance (+/-) Value Nasdaq Composite -0.70% 15,973.17 S&P 500 Index -0.13% 5,117.09 Dow Industrials -0.02% 38,714.77 Russell 2000 -2.08% 2,039.32 Analyst Color: Weighing in on the market weakness, Carson Group’s Ryan Detrick highlighted historical data that should ...Full story available on Benzinga.com.....»»
EMBRAER EARNINGS RESULTS 4th QUARTER 2023 and FISCAL YEAR 2023
SÃO PAULO, March 18, 2024 /PRNewswire/ -- EMBRAER S.A. (NYSE:ERJ, B3: EMBR3)) releases its FOURTH Quarter 2023 AND FISCAL YEAR 2023 Earnings Results. HIGHLIGHTS Embraer delivered 75 jets in 4Q23, of which 25 were commercial aircraft, 49 were executive jets (30 light and 19 medium) and 1 was a military C-390. In 2023, the company delivered a total of 181 jets, of which 64 were commercial aircraft, 115 were executive jets (74 light and 41 medium) and 2 were military C-390. Embraer's deliveries increased 13% year-on-year (yoy) when compared to the 160 jets in 2022. The company continues to face supply chain delays which have negatively impacted 2023 results. Firm order backlog ended 4Q23 at US$18.7 billion, the highest number recorded over the past 6 years. Executive and Commercial Aviation registered book-to-bill in excess of 1:1. Meanwhile, Services & Support backlog reached US$3.1 billion - the highest ever registered. Revenues totaled US$1,975 million in 4Q23 and ...Full story available on Benzinga.com.....»»
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: Record total revenue of $52.5 million for the full-year 2023, and total revenue of $13.8 million for the fourth quarter of 2023. Record 137,650 AVISE® CTD tests performed for the full-year 2023, including 30,438 tests for the fourth quarter of 2023. Over 900,000 AVISE® CTD tests performed to date since launch. AVISE® CTD trailing twelve-month average selling price (ASP) of $336, an increase of $51 over the course of the year. Delivered 56% gross margin for full-year 2023 and 59% for the fourth quarter of 2023. Net loss of $23.7 million for the full-year 2023 and $5.6 million for the fourth quarter of 2023. Adjusted EBITDA of $(17.1) million for the full-year 2023 and $(3.9) million in the fourth quarter of 2023. Cash balance of $36.5 million at year-end 2023. "I am extremely proud of our team's commitment and hard work this past year. We transformed quite a bit at Exagen and together, we are steering the company towards profitability, with a sharp focus on increasing ASP while diligently driving down expenses and responsibly managing cash. The progress we've made in the past year has significantly bolstered the health of our organization. We look forward to serving our clinicians and patients in 2024 with a renewed organization which is very much focused on reaching our operating goals. Our strategy has been validated and I'm confident that the best is yet to come for Exagen," said John Aballi, President and Chief Executive Officer. Fourth Quarter 2023 Financial Results Total revenue for the fourth quarter of 2023 and 2022 was $13.8 million and $12.8 million, respectively. Total gross margin was 59.2% in the fourth quarter of 2023 compared to 50.9% in the fourth quarter of 2022. The increase in gross margin percentage was primarily driven by an increase in ASP. Operating expenses were $18.9 million in the fourth quarter of 2023, compared to $27.3 million in the fourth quarter of 2022. The year-over-year decreases in operating expenses in the fourth quarter was primarily driven by lower selling, general and administrative expenses due to decreases in personnel costs and lower research and development expenses. For the fourth quarter of 2023, net loss was $5.6 million, compared to a net loss of $14.4 million for the fourth quarter of 2022 (which includes a $5.5 million impairment of goodwill that we recognized in the fourth quarter of 2022). Adjusted EBITDA was $(3.9) million for the fourth quarter of 2023 compared to $(13.4) million for the fourth quarter of 2022. A reconciliation of non-GAAP adjusted EBITDA is provided in the financial schedules that are part of this press release. An explanation of this non-GAAP financial measures is also included below under the heading "Use of Non-GAAP Financial Measures (unaudited)." Full-Year 2023 Financial Results Total revenue for full-year 2023 was $52.5 million, compared with $45.6 million for full-year 2022. Total gross margin was 56.1% for the full-year 2023 compared to 46.9% in 2022. Operating expenses were $75.4 million for the full-year 2023, compared with $91.6 million for the full-year 2022. Net loss was $23.7 million for the full year of 2023, compared with $47.4 million for the full year of 2022. Adjusted EBITDA was $(17.1) million for the full-year 2023 compared to $(39.8) million during the same period in 2022. Cash and cash equivalents were approximately $36.5 million as of December 31, 2023 and our accounts receivables were $6.5 million as of December 31, 2023. Guidance For full-year 2024 revenue, we are providing guidance of approximately $54 million. For first quarter 2024 revenue, we are providing a guidance range of $13.0 million to $13.5 million. For full-year 2024, we believe our adjusted EBITDA will be better than negative $20 million. Given our continued improved performance, we believe our existing cash and cash equivalents are adequate to meet our anticipated cash requirements into 2026. Conference CallA conference call to provide a business update and review fourth quarter and full-year 2023 financial results is scheduled for today March 18, 2024 at 8:30 AM Eastern Time (5:30 AM Pacific Time). Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Additionally, a link to a live webcast of the call will be available in the Investor Relations section of Exagen's website at investors.exagen.com. Participants are asked to join a few minutes prior to the call to register for the event. A replay of the conference call will be available until Monday, April 1, 2024 at 11:59 PM Eastern Time (8:59 PM Pacific Time). Interested parties may access the replay by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13743861. A link to the replay of the webcast will also be available in the investor relations section of Exagen's website. Use of Non-GAAP Financial Measures (UNAUDITED)In this release, we use the metrics adjusted EBITDA, which is not calculated in accordance with generally accepted accounting principles in the United States (GAAP) and is a non-GAAP financial measure. Adjusted EBITDA excludes from net loss interest income (expense), income tax (expense) benefit, depreciation and amortization expense, and stock-based compensation expense. We use adjusted EBITDA internally because we believe these metrics provide useful supplemental information in assessing our operating performance reported in accordance with GAAP. We believe adjusted EBITDA may enhance an evaluation of our operating performance because it excludes the impact of prior decisions made about capital investment, financing, investing and certain expenses we believe are not indicative of our ongoing performance. However, this non-GAAP financial measure may be different from non-GAAP financial measures used by other companies, even when the same or similarly titled terms are used to identify such measures, limiting their usefulness for comparative purposes. This non-GAAP financial measure is not meant to be considered in isolation or used as a substitute for net loss reported in accordance with GAAP, should be considered in conjunction with our financial information presented in accordance with GAAP, has no standardized meaning prescribed by GAAP, is unaudited, and is not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that we may exclude for purposes of these non-GAAP financial measures, and we may in the future cease to exclude items that we have historically excluded for purposes of these non-GAAP financial measures. Likewise, we may determine to modify the nature of adjustments to arrive at these non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measure as used by us in this press release and the accompanying reconciliation table have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Accordingly, investors should not place undue reliance on non-GAAP financial measures. About ExagenExagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes. Exagen is located in San Diego County, California. For more information, please visit Exagen.com or follow @ExagenInc on X (formally known as Twitter). Forward Looking StatementsExagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen's goals, strategies and ambitions; potential future financial and business performance; the potential utility and effectiveness of Exagen's services and testing solutions; potential shareholder value and growth and 2024 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen's business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen's commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen's ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen's testing products, including Exagen's ability to collect on funds due; Exagen's ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen's business; and other risks described in Exagen's prior press releases and Exagen's filings with the Securities and Exchange Commission ("SEC"), including under the heading "Risk Factors" in Exagen's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 18, 2024 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact:Ryan DouglasExagen Inc.ir@exagen.com760.560.1525 Exagen Inc.Statements of Operations(in thousands, except share and per share data) Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 (Unaudited) Revenue $ 13,765 $ 12,837 $ 52,548 $ 45,563 Operating expenses: Costs of revenue 5,620 6,309 23,092 24,214 Selling, general and administrative expenses 12,216 12,812 47,428 52,018 Research and development expenses 1,076 2,701 4,865 9,876 Goodwill impairment —.....»»
Nano Labs Announces Second Half of 2023 Financial Results
Nano Labs Announces Second Half of 2023 Financial Results.....»»